Article

Down-regulation of Plasminogen Activator Inhibitor 1 Expression Promotes Myocardial Neovascularization by Bone Marrow Progenitors

Department of Surgery and Department of Medicine, Columbia University, New York, NY 10032
Journal of Experimental Medicine (Impact Factor: 13.91). 01/2005; 200(12):1657-66. DOI: 10.1084/jem.20040221
Source: PubMed

ABSTRACT Human adult bone marrow-derived endothelial progenitors, or angioblasts, induce neovascularization of infarcted myocardium via mechanisms involving both cell surface urokinase-type plasminogen activator, and interactions between beta integrins and tissue vitronectin. Because each of these processes is regulated by plasminogen activator inhibitor (PAI)-1, we selectively down-regulated PAI-1 mRNA in the adult heart to examine the effects on postinfarct neovascularization and myocardial function. Sequence-specific catalytic DNA enzymes inhibited rat PAI-1 mRNA and protein expression in peri-infarct endothelium within 48 h of administration, and maintained down-regulation for at least 2 wk. PAI-1 inhibition enhanced vitronectin-dependent transendothelial migration of human bone marrow-derived CD34+ cells, and resulted in a striking augmentation of angioblast-dependent neovascularization. Development of large, thin-walled vessels at the peri-infarct region was accompanied by induction of proliferation and regeneration of endogenous cardiomyocytes and functional cardiac recovery. These results identify a causal relationship between elevated PAI-1 levels and poor outcome in patients with myocardial infarction through mechanisms that directly inhibit bone marrow-dependent neovascularization. Strategies that reduce myocardial PAI-1 expression appear capable of enhancing cardiac neovascularization, regeneration, and functional recovery after ischemic insult.

Download full-text

Full-text

Available from: Tetsunori Seki, Dec 23, 2013
0 Followers
 · 
78 Views
  • Source
    • "EPCs from patients with more extensive collateral development produced more colony-forming units, fewer senescent cells, and a greater concentration of bFGF in the supernatant of the culture medium (Matsuo et al., 2006). Notably, the extent of collateral formation and the number of circulating EPCs correlate inversely with insulin resistance, adiponectin level, PAI-1 concentration (He et al., 2006; Ouchi et al., 2004; Xiang et al., 2004) and with many of the characteristics associated with metabolic syndrome (i.e., a combination of medical disorders that increase the risk of developing cardiovascular disease and diabetes) (Mouquet et al., 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cell-based therapy has emerged as a promising therapeutic tool for treatment of ischemic cardiovascular disease. Both unselected bone marrow-derived mononuclear cells (BMNCs), which include stem/progenitor cells and several other cell types, and endothelial progenitor cells (EPCs), a subpopulation of BMNCs, display regenerative potential in ischemic tissue. Abundant evidence supports the involvement of EPCs in capillary growth, and EPCs also appear to participate in the formation of collateral vessels. Collectively, these effects have led to improved perfusion and functional recovery in animal models of myocardial and peripheral ischemia, and in early clinical trials, the therapeutic administration of EPCs to patients with myocardial infarction or chronic angina has been associated with positive trends in perfusion. EPCs also contribute to endothelial repair and may, consequently, impede the development or progression of arteriosclerosis. This review provides a brief summary of the preclinical and clinical evidence for the role of EPCs in blood-vessel formation and repair during ischemic cardiovascular disease.
    Microvascular Research 02/2010; 79(3):200-6. DOI:10.1016/j.mvr.2010.01.012 · 2.43 Impact Factor
  • Source
    • "Injection of this DNAzyme into the peri-infarct zone following AMI in the rat resulted in decreased PAI-1 expression up to 2 weeks posttreatment . Improved neovascularization of the infarcted tissue was demonstrated by increased transmigration of tagged human adult bone marrow-derived endothelial progenitors (angioblasts) and increased capillary density of human origin, indicating that the inhibitory effect of PAI-1 on plasmin generation and adhesion mediators had been countered by PAI-1 DNAzyme treatment (Xiang et al., 2004). Further work by this group with PAI-1 DNAzyme delivery to infarcted mouse hearts revealed not only PAI-1 inhibition and improved neovascularization, but also decreased apoptosis in the peri-infarct region and improved cardiac function, as measured by myocardial ejection fraction (Xiang et al., 2005a). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Gene silencing techniques are gaining increasing popularity in the literature, both as a tool for unravelling gene function and to potentially deliver therapeutic benefit, especially in the context of cardiovascular disease. Gene-specific catalytic DNA molecules, or DNAzymes, have shown promise in ameliorating the effects of myocardial ischaemia reperfusion injury and in-stent restenosis in various animal models, demonstrating that these agents may be useful in a clinical setting. A review of the recent advances in the use of DNAzymes in treating cardiovascular disease is therefore essential given the increasing clinical burden of cardiovascular disease worldwide. We have thus sought to firstly provide background into the construct and mechanism of action of DNAzymes, with a discussion of recent improvements in design. Secondly, we have examined the effects of DNAzyme-mediated gene inhibition in in vitro studies of both endothelial and smooth muscle migration and proliferation, as well as in vivo models of acute myocardial infraction and neointima formation. Lastly we compare DNAzymes with other gene silencing tools and discuss issues involved in successfully delivering these drugs in a clinical setting.
    British Journal of Pharmacology 07/2008; 154(4):741-8. DOI:10.1038/bjp.2008.145 · 4.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Obesity has assumed epidemic proportions and is expected to decrease the life expectancy of current and future generations by its cardiovascular complications and other associated chronic diseases. Recognizing the gravity of this trend, the American Heart Association recently identified obesity as an independent and important modifiable risk factor for cardiovascular disease. Obesity is known to cluster with other cardiovascular and metabolic risk factors constituting the cardiometabolic syndrome. The pathophysiogic link between obesity and cardiovascular disease is complex and involves multiple metabolic and inflammatory risk factors. In an attempt to better elucidate this major public health problem, this article reviews obesity as an epidemic, the structural and functional changes in the cardiovascular system as a result of obesity, and the pathophysiology of obesity-related cardiomyopathy. The sheer magnitude of the problem of obesity with its immense cardiovascular consequences warrants immediate intervention.
    Current Cardiovascular Risk Reports 03/2008; 2(2). DOI:10.1007/s12170-008-0022-3
Show more